Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK
ConclusionIntravitreal ranibizumab is a highly cost-effective intervention for the treatment of CNV due to causes other than nAMD and PM as it delivers substantial QALY gains to patients while making cost savings vs. BSC.FundingNovartis Pharmaceuticals UK Ltd.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Blindness | Drugs & Pharmacology | Eyes | Lucentis | Myopia (short sighted) | Opthalmology | Ranibizumab Injection | Rare Diseases | Study | UK Health